Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00940225 · ClinicalTrials.gov registry record · Phase 2
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
A Phase 2 study of Cancer and Solid Tumors, sponsored by Exelixis.
- Completed
- Registry status
- Phase 2
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT00940225 is a Phase 2 study of Cancer and Solid Tumors that has completed, run by Exelixis. The registered enrollment target is 730 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00940225, a Phase 2 study of Cancer and Solid Tumors, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabozantinib
Study Locations (20)
California
- University of California Davis Cancer Center - Sacramento
- University of California, San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Missouri
- University of Missouri Health Care - Columbia
- Kansas City Cancer Center - Lee's Summit
- Midwest Hematology Oncology Consultants - St Louis
Florida
- Florida Cancer Specialists - Fort Myers
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Michigan
- University of Michigan Health System - Ann Arbor
- Wayne State University - Detroit
New York
- NYU Clinical Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Pinnacle Oncology of Arizona - Scottsdale
Colorado
- Rocky Mountain Cancer Centers - Denver
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2009-09 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00940225
The ClinicalTrials.gov registry entry for NCT00940225 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00940225 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT00940225 about?
NCT00940225 is a clinical study titled "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies". This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
What is the current status of trial NCT00940225?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 730 participants. The study started on 2009-09. Estimated completion is 2014-06.
What conditions does trial NCT00940225 study?
This clinical trial studies the following conditions: Cancer, Solid Tumors.
What interventions are being tested in trial NCT00940225?
The interventions under investigation include: Placebo (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT00940225?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00940225 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.